AlloMap is a non-invasive genomic test that helps reassure clinicians of the absence of acute cellular rejection in heart transplant patients*.

Click on the video to watch Darren Tayama, M.D., explain the clinical fundamentals of using AlloMap testing in clinical practice.

*Absence is defined here as the very low probability of moderate/severe acute cellular rejection as measured by the negative predictive value. AlloMap test results are only to be used in conjunction with standard clinical assessment.